Human pharmacology and abuse potential of meptazinol

Rolley E. Johnson, Donald R. Jasinski

Research output: Contribution to journalArticle

Abstract

Meptazinol was assessed in nine opioid abusers according to a double-blind, randomized, crossover design to determine if it produced typical morphine effects. A comparison of physiologic and subjective effects was made between morphine, 7.5, 15, and 30 mg, meptazinol, 70, 140, and 280 mg, and placebo. Both drugs constricted pupils. Meptazinol,140 and 280 mg, decreased body temperature. Valid relative potency estimates of morphine to meptazinol were obtained for self-reported liking, opiate symptoms, and pupillary constriction. Meptazinol did not increase euphoria or sedation scale scores but did increase dysphoria scale scores. In the therapeutic dose range, meptazinol produced miosis, morphine-like identification and symptoms, limited liking, and some dysphoria. Dysphoria predominated at the 280 mg dose of meptazinol. From these data, it is concluded that meptazinol is not a typical morphine-like drug and has limited abuse potential.

Original languageEnglish (US)
Pages (from-to)426-433
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume41
Issue number4
StatePublished - Apr 1987

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Human pharmacology and abuse potential of meptazinol'. Together they form a unique fingerprint.

  • Cite this

    Johnson, R. E., & Jasinski, D. R. (1987). Human pharmacology and abuse potential of meptazinol. Clinical Pharmacology and Therapeutics, 41(4), 426-433.